FDA Intensifies Crackdown on Celebrity and Weight-Loss Drug Ads

The FDA has issued multiple warning letters to pharmaceutical companies, including Eli Lilly and Novo Nordisk, for misleading drug advertisements across various media, emphasizing concerns over safety disclosures and the portrayal of drugs in a way that may mislead consumers, as part of a broader crackdown on deceptive marketing practices in the industry.